Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine

Melissa L. Fishel, Michael P. Gamcsik, Shannon M. Delaney, Eleanor G. Zuhowski, Veronica M. Maher, Theodore Karrison, Robert C. Moschel, Merrill J. Egorin, M. Eileen Dolan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Modulation of platinating agent cytotoxicity has important clinical implications as a result of their widespread use in the treatment of many different cancers. O6-Benzylguanine (BG) enhances the cytotoxicity of cisplatin against several human tumor lines. The purpose of our work was to elucidate whether BG affects pathways prior to DNA damage (i.e., glutathione, GSH) or following DNA damage (i.e., nucleotide excision repair, NER). Methods: In efforts to determine the mechanism of enhancement we: (1) evaluated whether different sequences of BG plus cisplatin treatment differed in their ability to enhance cisplatin-induced cytotoxicity and DNA platination; (2) determined the effect of BG on GSH and glutathione S-transferase (GST) activity and; (3) determined whether BG enhanced cisplatin-induced cytotoxicity in cells lacking specific enzymes in the NER pathway. Colony-forming assay, atomic absorption spectroscopy and HPLC were employed to measure tumor cell growth inhibition, quantitate the amount of platinum on DNA, and determine intracellular GSH concentrations, respectively. Results: Increased cytotoxicity and platination of DNA was observed when cells were exposed to BG prior to and/or during cisplatin treatment and not when BG followed cisplatin treatment. BG did not significantly alter GST activity with minimal depletion of GSH. In contrast, buthionine sulfoximine (BSO) caused a much more dramatic decrease in GSH than BG that was not accompanied by a dramatic increase in sensitivity to cisplatin. Furthermore, BG enhanced the cytotoxicity of cisplatin in a series of cell lines deficient in NER. Conclusions: Overall, our results suggest that the mechanism of enhancement involves neither the GSH nor the NER pathways, but triggers an event prior to DNA platination damage that ultimately results in increased cytotoxicity, apoptosis and increased platination levels.

Original languageEnglish (US)
Pages (from-to)333-342
Number of pages10
JournalCancer Chemotherapy and Pharmacology
Volume55
Issue number4
DOIs
StatePublished - Apr 1 2005

Fingerprint

DNA Repair
Cisplatin
Cytotoxicity
Glutathione
Repair
Nucleotides
Modulation
DNA
DNA Damage
Glutathione Transferase
Tumors
Buthionine Sulfoximine
Atomic spectroscopy
Neoplasms
O(6)-benzylguanine
Cell growth
Platinum
Absorption spectroscopy
Assays
Spectrum Analysis

Keywords

  • Chemotherapy
  • Cisplatin
  • Modulation

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. / Fishel, Melissa L.; Gamcsik, Michael P.; Delaney, Shannon M.; Zuhowski, Eleanor G.; Maher, Veronica M.; Karrison, Theodore; Moschel, Robert C.; Egorin, Merrill J.; Dolan, M. Eileen.

In: Cancer Chemotherapy and Pharmacology, Vol. 55, No. 4, 01.04.2005, p. 333-342.

Research output: Contribution to journalArticle

Fishel, ML, Gamcsik, MP, Delaney, SM, Zuhowski, EG, Maher, VM, Karrison, T, Moschel, RC, Egorin, MJ & Dolan, ME 2005, 'Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine', Cancer Chemotherapy and Pharmacology, vol. 55, no. 4, pp. 333-342. https://doi.org/10.1007/s00280-004-0901-3
Fishel, Melissa L. ; Gamcsik, Michael P. ; Delaney, Shannon M. ; Zuhowski, Eleanor G. ; Maher, Veronica M. ; Karrison, Theodore ; Moschel, Robert C. ; Egorin, Merrill J. ; Dolan, M. Eileen. / Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. In: Cancer Chemotherapy and Pharmacology. 2005 ; Vol. 55, No. 4. pp. 333-342.
@article{1748bca2e8f048a79f87a1f6a8aacc9a,
title = "Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine",
abstract = "Purpose: Modulation of platinating agent cytotoxicity has important clinical implications as a result of their widespread use in the treatment of many different cancers. O6-Benzylguanine (BG) enhances the cytotoxicity of cisplatin against several human tumor lines. The purpose of our work was to elucidate whether BG affects pathways prior to DNA damage (i.e., glutathione, GSH) or following DNA damage (i.e., nucleotide excision repair, NER). Methods: In efforts to determine the mechanism of enhancement we: (1) evaluated whether different sequences of BG plus cisplatin treatment differed in their ability to enhance cisplatin-induced cytotoxicity and DNA platination; (2) determined the effect of BG on GSH and glutathione S-transferase (GST) activity and; (3) determined whether BG enhanced cisplatin-induced cytotoxicity in cells lacking specific enzymes in the NER pathway. Colony-forming assay, atomic absorption spectroscopy and HPLC were employed to measure tumor cell growth inhibition, quantitate the amount of platinum on DNA, and determine intracellular GSH concentrations, respectively. Results: Increased cytotoxicity and platination of DNA was observed when cells were exposed to BG prior to and/or during cisplatin treatment and not when BG followed cisplatin treatment. BG did not significantly alter GST activity with minimal depletion of GSH. In contrast, buthionine sulfoximine (BSO) caused a much more dramatic decrease in GSH than BG that was not accompanied by a dramatic increase in sensitivity to cisplatin. Furthermore, BG enhanced the cytotoxicity of cisplatin in a series of cell lines deficient in NER. Conclusions: Overall, our results suggest that the mechanism of enhancement involves neither the GSH nor the NER pathways, but triggers an event prior to DNA platination damage that ultimately results in increased cytotoxicity, apoptosis and increased platination levels.",
keywords = "Chemotherapy, Cisplatin, Modulation",
author = "Fishel, {Melissa L.} and Gamcsik, {Michael P.} and Delaney, {Shannon M.} and Zuhowski, {Eleanor G.} and Maher, {Veronica M.} and Theodore Karrison and Moschel, {Robert C.} and Egorin, {Merrill J.} and Dolan, {M. Eileen}",
year = "2005",
month = "4",
day = "1",
doi = "10.1007/s00280-004-0901-3",
language = "English (US)",
volume = "55",
pages = "333--342",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine

AU - Fishel, Melissa L.

AU - Gamcsik, Michael P.

AU - Delaney, Shannon M.

AU - Zuhowski, Eleanor G.

AU - Maher, Veronica M.

AU - Karrison, Theodore

AU - Moschel, Robert C.

AU - Egorin, Merrill J.

AU - Dolan, M. Eileen

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Purpose: Modulation of platinating agent cytotoxicity has important clinical implications as a result of their widespread use in the treatment of many different cancers. O6-Benzylguanine (BG) enhances the cytotoxicity of cisplatin against several human tumor lines. The purpose of our work was to elucidate whether BG affects pathways prior to DNA damage (i.e., glutathione, GSH) or following DNA damage (i.e., nucleotide excision repair, NER). Methods: In efforts to determine the mechanism of enhancement we: (1) evaluated whether different sequences of BG plus cisplatin treatment differed in their ability to enhance cisplatin-induced cytotoxicity and DNA platination; (2) determined the effect of BG on GSH and glutathione S-transferase (GST) activity and; (3) determined whether BG enhanced cisplatin-induced cytotoxicity in cells lacking specific enzymes in the NER pathway. Colony-forming assay, atomic absorption spectroscopy and HPLC were employed to measure tumor cell growth inhibition, quantitate the amount of platinum on DNA, and determine intracellular GSH concentrations, respectively. Results: Increased cytotoxicity and platination of DNA was observed when cells were exposed to BG prior to and/or during cisplatin treatment and not when BG followed cisplatin treatment. BG did not significantly alter GST activity with minimal depletion of GSH. In contrast, buthionine sulfoximine (BSO) caused a much more dramatic decrease in GSH than BG that was not accompanied by a dramatic increase in sensitivity to cisplatin. Furthermore, BG enhanced the cytotoxicity of cisplatin in a series of cell lines deficient in NER. Conclusions: Overall, our results suggest that the mechanism of enhancement involves neither the GSH nor the NER pathways, but triggers an event prior to DNA platination damage that ultimately results in increased cytotoxicity, apoptosis and increased platination levels.

AB - Purpose: Modulation of platinating agent cytotoxicity has important clinical implications as a result of their widespread use in the treatment of many different cancers. O6-Benzylguanine (BG) enhances the cytotoxicity of cisplatin against several human tumor lines. The purpose of our work was to elucidate whether BG affects pathways prior to DNA damage (i.e., glutathione, GSH) or following DNA damage (i.e., nucleotide excision repair, NER). Methods: In efforts to determine the mechanism of enhancement we: (1) evaluated whether different sequences of BG plus cisplatin treatment differed in their ability to enhance cisplatin-induced cytotoxicity and DNA platination; (2) determined the effect of BG on GSH and glutathione S-transferase (GST) activity and; (3) determined whether BG enhanced cisplatin-induced cytotoxicity in cells lacking specific enzymes in the NER pathway. Colony-forming assay, atomic absorption spectroscopy and HPLC were employed to measure tumor cell growth inhibition, quantitate the amount of platinum on DNA, and determine intracellular GSH concentrations, respectively. Results: Increased cytotoxicity and platination of DNA was observed when cells were exposed to BG prior to and/or during cisplatin treatment and not when BG followed cisplatin treatment. BG did not significantly alter GST activity with minimal depletion of GSH. In contrast, buthionine sulfoximine (BSO) caused a much more dramatic decrease in GSH than BG that was not accompanied by a dramatic increase in sensitivity to cisplatin. Furthermore, BG enhanced the cytotoxicity of cisplatin in a series of cell lines deficient in NER. Conclusions: Overall, our results suggest that the mechanism of enhancement involves neither the GSH nor the NER pathways, but triggers an event prior to DNA platination damage that ultimately results in increased cytotoxicity, apoptosis and increased platination levels.

KW - Chemotherapy

KW - Cisplatin

KW - Modulation

UR - http://www.scopus.com/inward/record.url?scp=15044344097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044344097&partnerID=8YFLogxK

U2 - 10.1007/s00280-004-0901-3

DO - 10.1007/s00280-004-0901-3

M3 - Article

C2 - 15723259

AN - SCOPUS:15044344097

VL - 55

SP - 333

EP - 342

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -